Posted by Michael Wonder on 24 Nov 2020
Lilly and the Government of Canada sign an agreement for the supply of bamlanivimab to treat COVID-19 in Canada
24 November 2020 - Bamlanivimab is a SARS-CoV-2-neutralising antibody that emerged from the collaboration between Lilly and Vancouver-based AbCellera.
Eli Lilly Canada announced today that Lilly and the Government of Canada have signed an agreement for the supply of bamlanivimab to Canada. Lilly will supply Canada with an initial quantity of 26,000 doses of bamlanivimab over the three month period between December 2020 and February 2021, for US$32.5 million.
